NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis Inc., (OTCBB: ADXS, http://www.advaxis.com.), a developmental biotechnology company, garnered national media attention after having presented landmark results from it’s first-in-man clinical trial of its flagship drug candidate, Lovaxin C – a live Listeria monocytogenes-based cancer vaccine – at the annual meeting of the American Association for Cancer Research (“AACR”), held earlier this week in San Diego, CA.
